Nivolumab plus ipilimumab and nivolumab alone have been shown to improve survival, as compared with ipilimumab alone, in advanced melanoma. New research findings over 10 years of follow-up are ...

Their spatial epidemiologic study in the Journal of Investigative Dermatology, published by Elsevier, provides critical ...